Provectus Biopharmaceuticals, Inc. (PNK:PVCT) Q1 2024 Earnings Call Transcript

If approved, Provectus may undertake a reverse split when the company’s Board of Directors believes doing so would be in the best interest of Prevectus shareholders. Thank you for joining us today on this conference call. I have some closing remarks. Our vision for Provectus is based upon our belief that maximizing shareholder value over time comes from maximizing patient outcomes from treatment and patient access to medicine. We believe enhanced shareholder value could come from expanding Provectus medical science platform to treat diseases beyond cancer. This expansion could potentially come through compelling data and or potential business spinouts. In raising further investment Provectus will continue its efforts to try to balance time based corporate needs with the potential cost of shareholder dilution through disciplined capital raising and effective corporate development.

The regulatory, pharma and investment communities want randomized controlled trial data of PV-10 compared to standard of care for a relevant, distinctive cancer indication. We believe doing the right deal at the right time because of compelling comprehensive clinical data sets can potentially lead to a much better outcome for shareholders. The first data set could come from the company’s hepatic metastases pancreatic cancer program. By collaborating with our labs, Provectus plans to increase its investor communication and expand its visibility and outreach to the investment community. Topics today will be elaborated on in greater detail on Provectus’ Substack including providing the script that we used for this call and a recording of it, which will also be available on the company’s website along with the call’s slides.

We look forward to hosting you at Provectus’ 2024 stockholder meeting in Knoxville in the second quarter. The company is evaluating, possibly webcasting the meeting for those shareholders who cannot attend in person. Finally, I want to personally thank each PRH investor for your confidence and support in our work. You have enabled our continued progress. Your investments, totaling approximately $30 million in an antidilutive fashion for common shareholders, have empowered the revelation of an array of promising applications of Provectus’ Rose Bengal Sodium in cancer and other diseases. I contend that the promise of these applications is being revealed by the exceptional physicians, researchers and medical centers we are working within our efforts to one-day serve patients around the world.

Thank you, Alyssa.

Alyssa Barry: Thank you, Ed and Dominic. Thank you everyone for attending the first quarter 2024 conference call of Provectus Biopharmaceuticals. We look forward to speaking with you this summer. Have wonderful rest of your day.

Operator: This concludes today’s conference call. You may disconnect your lines. Thank you for participating and have a pleasant day.

Q – :